Buckeye's lead technology, MACROESIS^TM (patent pending) shows great clinical promise to overcome earlier limitations and open the door to a broad range of active compounds.  It is ideal for delivering efficacious dosages in a non-invasive and safe manner. MACROESIS^TM goes significantly beyond the promise of iontophoresis by utilizing both AC and DC electrochemistry delivered through disposable electrodes and targeted drug delivery to actively push drugs to where they are needed.  

MACROESIS^TM drug delivery utilizes electokinesis, a low-voltage electric current to induce fluid and particle movement. It involves the application of an electromotive force to transport ions and neutral molecules through a solid or liquid medium, in this case the protective stratum corneum, and into the epidermis. Ionized drugs (charged molecules) are transported actively by the force of the applied electrical field (electrorepulsion). In iontophoresis, like charges repel, so positively charged ions are driven into the skin at the anode (positive electrode), while negatively charged ions are driven into the skin at the cathode (negative electrode). Neutral, water soluble drug molecules are transported by electroosmosis, the bulk fluid flow associated with cation (positively charged molecules) transport by an electric field.  Two electrodes are used in conjunction with the patient’s skin to form a closed circuit, which allows the flow of current. 

MACROESISTM applies proprietary technology to polarize molecules, allowing a much wider classes of drugs to be take advantage of this process.  Our initial focus is onchomycosis ($1.6 billion market in US alone) in which antifungal drugs can be driven right through the nail cuticle to the actual location of the fungus growth.  Initial prototypic tests show great promise for onchomychosis as well as numerous other therapeutic markets including herpes labialis and catheter infections.